Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variantsZhiqiang Ku, Zhiqiang An, Hang Su et al.|Nature|2021Cited by 186
Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety ProfileKeyu Li, Bruce A. Keyt, Rui Yun et al.|Blood|2022Cited by 10
An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoVHailong Guo, Tong‐Ming Fu, Bomsoo Cho et al.|Emerging Microbes & Infections|2023Cited by 5
Abstract 5664: A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine releaseRamesh Baliga, Bruce A. Keyt, Keyu Li et al.|Cancer Research|2020Cited by 3
Abstract 2959: Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent mechanismsKeyu Li, Bruce A. Keyt, Rui Yun et al.|Cancer Research|2023Cited by 2